376 related articles for article (PubMed ID: 14726483)
41. RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing.
Ong AAL; Tan J; Bhadra M; Dezanet C; Patil KM; Chong MS; Kierzek R; Decout JL; Roca X; Chen G
Molecules; 2019 Aug; 24(16):. PubMed ID: 31434312
[TBL] [Abstract][Full Text] [Related]
42. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
[TBL] [Abstract][Full Text] [Related]
43. A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides.
Takata R; Makado G; Kitamura A; Watanabe H; Wada T
RNA Biol; 2016; 13(3):279-89. PubMed ID: 26890856
[TBL] [Abstract][Full Text] [Related]
44. Gymnotic Delivery of LNA Mixmers Targeting Viral SREs Induces HIV-1 mRNA Degradation.
Hillebrand F; Ostermann PN; Müller L; Degrandi D; Erkelenz S; Widera M; Pfeffer K; Schaal H
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832397
[TBL] [Abstract][Full Text] [Related]
45. Locked nucleic acid oligonucleotides: the next generation of antisense agents?
Grünweller A; Hartmann RK
BioDrugs; 2007; 21(4):235-43. PubMed ID: 17628121
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts.
Maruyama R; Touznik A; Yokota T
J Vis Exp; 2018 May; (135):. PubMed ID: 29806836
[TBL] [Abstract][Full Text] [Related]
47. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
[TBL] [Abstract][Full Text] [Related]
48. Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA.
Frieden M; Christensen SM; Mikkelsen ND; Rosenbohm C; Thrue CA; Westergaard M; Hansen HF; Ørum H; Koch T
Nucleic Acids Res; 2003 Nov; 31(21):6365-72. PubMed ID: 14576324
[TBL] [Abstract][Full Text] [Related]
49. Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro.
Shimo T; Tachibana K; Saito K; Yoshida T; Tomita E; Waki R; Yamamoto T; Doi T; Inoue T; Kawakami J; Obika S
Nucleic Acids Res; 2014 Jul; 42(12):8174-87. PubMed ID: 24935206
[TBL] [Abstract][Full Text] [Related]
50. RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.
Mutso M; Nikonov A; Pihlak A; Žusinaite E; Viru L; Selyutina A; Reintamm T; Kelve M; Saarma M; Karelson M; Merits A
PLoS One; 2015; 10(6):e0128686. PubMed ID: 26039055
[TBL] [Abstract][Full Text] [Related]
51. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides.
Villemaire J; Dion I; Elela SA; Chabot B
J Biol Chem; 2003 Dec; 278(50):50031-9. PubMed ID: 14522969
[TBL] [Abstract][Full Text] [Related]
52. Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites.
Jakobsen MR; Haasnoot J; Wengel J; Berkhout B; Kjems J
Retrovirology; 2007 Apr; 4():29. PubMed ID: 17459171
[TBL] [Abstract][Full Text] [Related]
53. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).
Jepsen JS; Pfundheller HM; Lykkesfeldt AE
Oligonucleotides; 2004; 14(2):147-56. PubMed ID: 15294077
[TBL] [Abstract][Full Text] [Related]
54. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.
Sierakowska H; Sambade MJ; Agrawal S; Kole R
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):12840-4. PubMed ID: 8917506
[TBL] [Abstract][Full Text] [Related]
55. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski Z; Kole R
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8673-7. PubMed ID: 8378346
[TBL] [Abstract][Full Text] [Related]
56. Repair of aberrant splicing in growth hormone receptor by antisense oligonucleotides targeting the splice sites of a pseudoexon.
David A; Srirangalingam U; Metherell LA; Khoo B; Clark AJ
J Clin Endocrinol Metab; 2010 Jul; 95(7):3542-6. PubMed ID: 20427506
[TBL] [Abstract][Full Text] [Related]
57. Overview of alternative oligonucleotide chemistries for exon skipping.
Saleh AF; Arzumanov AA; Gait MJ
Methods Mol Biol; 2012; 867():365-78. PubMed ID: 22454073
[TBL] [Abstract][Full Text] [Related]
58. Alpha-l-Locked Nucleic Acid-Modified Antisense Oligonucleotides Induce Efficient Splice Modulation In Vitro.
Raguraman P; Wang T; Ma L; Jørgensen PT; Wengel J; Veedu RN
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244535
[TBL] [Abstract][Full Text] [Related]
59. Construction of a tri-chromatic reporter cell line for the rapid and simple screening of splice-switching oligonucleotides targeting DMD exon 51 using high content screening.
Shimo T; Tachibana K; Obika S
PLoS One; 2018; 13(5):e0197373. PubMed ID: 29768479
[TBL] [Abstract][Full Text] [Related]
60. Antisense Oligonucleotide Design and Evaluation of Splice-Modulating Properties Using Cell-Based Assays.
Slijkerman R; Kremer H; van Wijk E
Methods Mol Biol; 2018; 1828():519-530. PubMed ID: 30171565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
